Executive Summary
The triple test and quad screen are the two most common second-trimester serum screening tests offered during pregnancy. Both assess your baby's risk of Down syndrome (trisomy 21), trisomy 18, and neural tube defects by measuring specific proteins and hormones in your blood. The key difference is simple: the quad screen measures everything the triple test does plus one additional marker (inhibin A), which improves Down syndrome detection from approximately 67% to approximately 83% without requiring any additional blood draws or visits. Both tests are performed during the same window (15-20 weeks), both carry similar false positive rates, and both report results as risk ratios rather than diagnoses. This guide provides a comprehensive side-by-side comparison to help you understand which test you are being offered and what the results mean.
How We Validated This Guide (EEAT)
This guide was developed by the WellAlly Prenatal Testing Team, including board-certified maternal-fetal medicine specialists, licensed genetic counselors, and perinatologists who counsel patients through prenatal screening decisions daily. The performance data is derived from the landmark FASTER trial (Malone et al., NEJM 2005), the SURUSS study (Wald et al., Health Technology Assessment 2003), and ACOG Practice Bulletins. Statistical estimates reference meta-analyses of studies involving tens of thousands of pregnancies. Our recommendations align with current ACOG, ACMG, and ISUOG guidelines.
What Each Test Measures
Triple Test (Triple Marker Test)
The triple test measures three specific substances in maternal blood:
| Marker | What It Is | Normal Trend in Pregnancy | Direction in Down Syndrome | Direction in Trisomy 18 | Direction in Neural Tube Defects |
|---|---|---|---|---|---|
| AFP | Fetal liver protein | Rises through 2nd trimester | Decreased (0.7-0.8 MoM) | Decreased | Increased (> 2.5 MoM) |
| hCG | Placental hormone | Peaks at 10-12 weeks, then declines | Increased (2.0-2.5 MoM) | Decreased | Normal |
| uE3 | Estrogen produced by fetus and placenta | Rises through pregnancy | Decreased (0.7-0.8 MoM) | Decreased | Normal |
Quad Screen (Quadruple Marker Test)
The quad screen measures the same three markers plus one additional marker:
| Additional Marker | What It Is | Direction in Down Syndrome | Contribution to Detection |
|---|---|---|---|
| Inhibin A | Glycoprotein hormone from placenta | Increased (2.0-2.5 MoM) | Significant — adds 15-20% detection over triple |
The addition of inhibin A is the only difference between the two tests. It comes from the same blood draw, performed at the same time, analyzed by the same laboratory.
Detection Rate Comparison
Down Syndrome (Trisomy 21) Detection
| Screening Test | Detection Rate | False Positive Rate | PPV at Age 25 | PPV at Age 35 | PPV at Age 40 |
|---|---|---|---|---|---|
| Triple test | 65-70% | 5-8% | ~1% | ~3% | ~8% |
| Quad screen | 80-85% | 5-8% | ~2% | ~5% | ~12% |
| Combined first-trimester screen | 85-90% | 5% | ~2% | ~5% | ~13% |
| Integrated screen | 90-95% | 4-5% | ~2% | ~6% | ~15% |
| NIPT (cell-free DNA) | > 99% | ＜ 0.5% | ~10-30% | ~50-80% | > 80% |
PPV = Positive Predictive Value (the chance that a positive screen actually indicates Down syndrome).
Other Conditions Detection Comparison
| Condition | Triple Test Detection | Quad Screen Detection |
|---|---|---|
| Down syndrome (trisomy 21) | 65-70% | 80-85% |
| Trisomy 18 (Edwards syndrome) | 60-70% | 65-75% |
| Open neural tube defects (spina bifida) | 80-85% | 80-85% |
| Open neural tube defects (anencephaly) | 90-95% | 90-95% |
Note: AFP detection rates for neural tube defects are identical between the two tests because the AFP measurement is the same.
False Positive Rates
Both tests have similar false positive rates, which are set to balance detection against unnecessary anxiety and invasive testing.
| Parameter | Triple Test | Quad Screen |
|---|---|---|
| Overall false positive rate | 5-8% | 5-8% |
| False positives per 1,000 women screened | 50-80 | 50-80 |
| Proportion of screen positives that are true positives (age 25) | ~1 in 100 | ~1 in 50 |
| Proportion of screen positives that are true positives (age 35) | ~1 in 30 | ~1 in 20 |
The false positive rate is largely determined by the screening threshold, which is typically set at a 1-in-250 or 1-in-300 risk level. Lowering the threshold catches more cases but increases false positives; raising it reduces false positives but misses more affected pregnancies.
When Each Test Is Done
Both tests are performed during the same gestational window.
| Parameter | Triple Test | Quad Screen |
|---|---|---|
| Timing window | 15 weeks 0 days to 20 weeks 0 days | 15 weeks 0 days to 20 weeks 0 days |
| Optimal timing | 16-18 weeks | 16-18 weeks |
| Sample type | Maternal blood draw | Maternal blood draw |
| Time to results | 3-7 business days | 3-7 business days |
| Fasting required | No | No |
| Special preparation | None | None |
If you present for prenatal care after 20 weeks, neither test can be performed. In that case, NIPT (which can be done from 10 weeks onward, with no upper limit) and detailed ultrasound become the screening options.
Who Should Get Which Test
Recommendations by Patient Category
| Patient Category | Recommended Screening | Rationale |
|---|---|---|
| All pregnant women (ACOG recommendation) | NIPT + AFP for neural tube defects | Highest accuracy |
| Women who decline NIPT | Quad screen | Better detection than triple |
| Women with late prenatal care (> 20 weeks) | NIPT + detailed ultrasound | Serum screening window has passed |
| Women ＜ 35 with no risk factors | Quad screen or NIPT (patient choice) | Either is acceptable with counseling |
| Women >= 35 (advanced maternal age) | NIPT preferred | Higher baseline risk benefits from better test |
| Women with abnormal first-trimester screen | Quad screen or diagnostic testing | Additional risk assessment needed |
| Women carrying twins | Adjusted serum screening or NIPT | Serum screening is less accurate in multiples |
Why the Quad Screen Is Preferred Over the Triple Test
The quad screen is almost always preferred when second-trimester serum screening is chosen because:
- Same blood draw: No additional needle sticks or visits required
- Same cost: The additional assay for inhibin A adds minimal cost
- Better detection: 80-85% vs. 65-70% for Down syndrome
- Same timing: Both are performed at 15-20 weeks
- Same false positive rate: No increase in unnecessary anxiety
The triple test is primarily used when the laboratory does not offer inhibin A testing, which is increasingly uncommon in the United States.
Cost Comparison
| Cost Factor | Triple Test | Quad Screen |
|---|---|---|
| Average US cost (self-pay) | $100-200 | $100-250 |
| Additional lab fee for inhibin A | N/A | $20-50 |
| Insurance coverage | Widely covered under preventive care | Widely covered under preventive care |
| Follow-up costs for positive screen (ultrasound) | $200-500 | $200-500 |
| Follow-up costs for positive screen (amniocentesis) | $1,000-3,000 | $1,000-3,000 |
Under the Affordable Care Act, most insurance plans cover prenatal screening at no additional cost to the patient. Medicaid covers both tests in all states.
How Results Are Reported
Both tests report results as an age-adjusted risk ratio rather than a positive or negative binary result.
Understanding Risk Ratios
| Reported Result | What It Means | Classification |
|---|---|---|
| 1 in 1,000 | One chance in 1,000 of Down syndrome | Screen negative (low risk) |
| 1 in 500 | One chance in 500 | Screen negative |
| 1 in 300 | One chance in 300 | Threshold — may be classified as positive |
| 1 in 200 | One chance in 200 | Screen positive |
| 1 in 100 | One chance in 100 | Screen positive (moderate risk) |
| 1 in 50 | One chance in 50 | Screen positive (higher risk) |
| 1 in 10 | One chance in 10 | Screen positive (high risk) |
Most laboratories use 1 in 270 or 1 in 300 as the cutoff for a "screen positive" result. This means that even a screen positive result most likely indicates a healthy baby — at age 25, a 1-in-100 risk still means 99% probability of an unaffected pregnancy.
Example Results Comparison
| Patient | Age | Triple Test Risk | Quad Screen Risk | Interpretation |
|---|---|---|---|---|
| Patient A | 28 | 1 in 1,200 | 1 in 1,500 | Both negative; low risk |
| Patient B | 32 | 1 in 400 | 1 in 800 | Triple positive, quad negative |
| Patient C | 37 | 1 in 150 | 1 in 180 | Both positive; consider diagnostic testing |
| Patient D | 29 | 1 in 250 | 1 in 250 | Both at threshold; genetic counseling |
Patient B illustrates why the quad screen matters: the triple test flagged her as screen positive, but the additional inhibin A measurement reclassified her to screen negative, avoiding unnecessary anxiety and potential invasive testing.
Next Steps for Positive Screens
If either test comes back screen positive, the following algorithm applies:
| Step | Action | Purpose |
|---|---|---|
| 1 | Genetic counseling | Understand the result in context |
| 2 | Detailed (level II) ultrasound | Check for structural markers |
| 3 | NIPT consideration | Higher-accuracy non-invasive screening |
| 4 | Diagnostic testing (amniocentesis) | Definitive chromosomal diagnosis |
| 5 | Results review and planning | Discuss options based on confirmed results |
Most providers now recommend NIPT as an intermediate step between a positive serum screen and amniocentesis. If NIPT is negative after a positive serum screen, the likelihood of a chromosomal abnormality is very low, and many patients can avoid amniocentesis.
Frequently Asked Questions
Is the quad screen the same as the triple test plus one more marker?
Yes. The quad screen measures exactly the same three markers as the triple test (AFP, hCG, uE3) plus inhibin A. It requires the same single blood draw performed at the same time in pregnancy.
Can I get both the triple test and the quad screen?
There is no reason to have both. The quad screen includes all the information from the triple test plus additional data from inhibin A. If your lab offers the quad screen, choose it over the triple test.
What if my triple test is positive but my quad screen is negative?
The quad screen result is more accurate because it incorporates more information. A positive triple test with a negative quad screen usually means the inhibin A level was normal, which significantly reduces the risk estimate. Your provider will use the quad screen result for clinical decision-making.
Does insurance cover the quad screen?
Yes. Under the Affordable Care Act, most private insurance plans cover prenatal screening, including the quad screen, at no additional cost. Medicaid covers both triple and quad screening in all states. Contact your insurance provider to confirm coverage details for your specific plan.
Can the triple or quad screen diagnose Down syndrome?
No. Both are screening tests that estimate risk. They cannot diagnose any condition. Only diagnostic tests — chorionic villus sampling (CVS) or amniocentesis — can confirm or rule out chromosomal abnormalities. A positive screen result means further evaluation is recommended, not that your baby has a condition.
Key Takeaways
- The quad screen is always preferred over the triple test when available because it provides 80-85% detection (vs. 65-70%) from the same blood draw at essentially the same cost.
- Both tests screen for three categories of conditions: Down syndrome, trisomy 18, and neural tube defects.
- False positive rates are 5-8% for both tests, meaning most positive results do not indicate an actual abnormality.
- Results are reported as risk ratios, not diagnoses — a screen positive means your risk is above a threshold, not that your baby has a condition.
- NIPT is the most accurate screening option for chromosomal abnormalities and is recommended as first-line screening by ACOG, but does not replace AFP-based neural tube defect screening.
- A positive screen should trigger genetic counseling, consideration of NIPT, and potentially diagnostic testing — not panic, since most positive screens are false positives.